Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Liminal BioSciences Inc. LMNL

Liminal BioSciences is a biopharmaceutical company focused on the discovery and development of novel, small molecule drug candidates for the treatment of patients suffering from fibrotic or inflammatory diseases that have a high unmet medical need. Liminal BioSciences operates on an integrated basis from our talent hubs in Laval, Quebec, Canada, and Cambridge, UK. Our common shares are listed for trading on the Nasdaq Global Market.


NDAQ:LMNL - Post by User

Bullboard Posts
Post by inventorson Aug 12, 2015 3:00pm
358 Views
Post# 24012003

Weather Forecast

Weather Forecast
Hold the Onions...the Plasminogen news is not the arcana that shareholders were expecting, but it was a value loaded...lol. This news was for other third participating parties...like partners...and enrollment patients...etc.
 
The great news will drift out soon after the CC with 4050 as mentioned by months end...IMHO.
 
The sp is sitting on top of the 200 moving average, so what is the problem...some have argued that this is bottom, and unless one is a Japanese candle trader...good luck with picking off a sticky day.
 
If by reason the sp wicks down between $2.05...$1.79, its to flush out the last of stop losses, and that is it. The rest is all gravy... and double that bottom number, which may take the sp to $3.58...$4.10...and $4.30 by today's $2.15'ish level...
 
Just as the SH article mentioned, 65% of the float is long, so what kind of question does one need to know? 'SH - what are you waiting for?'
 
There has been no dumping except China's currency, and we all know PL will provide all the answers by conference call.
 
PLI 4050, First in Class, Orphan, and is now going to get faster tracked.
 
FDA Phase I, II, and III is kind to the EPO standard, but Orphan is nascent with bits and pieces that is custom to its own process, and needs to be charted by milestones.
 
Get use to verbiage, new data is not finalized, it is material awareness that a significant micro milestone has been reached. Now others can feel confident that all systems are fine. Another pro-rate word, end of the month, quarter, year...is not fiscal year out, so to say. It's kind of a built in message to those whom needs assurance.
 
The only question is how all the measures are going, an updated forecast, and perhaps an overlay between the Euro FDA Commission and that of US FDA.
 

Bullboard Posts